2024-04-12T15:06:15-05:00 2023-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2022-07-01 231907729 JDRF INTERNATIONAL JDRF 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 ROBERT KING CFAO 2124797550 2024-04-08 1 ROBERT KING 999009999 0 EVAN W SEEKAMP P01910707 2127589700 2024-04-05 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z ROBERT KING 200 VESEY STREET NEW YORK NY 10281 351062168 0 X WWW.JDRF.ORG X 1970 PA IMPROVING LIVES BY ACCELERATING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D. SEE SCHEDULE O. 16 15 570 235000 46542 23845 205076492 190086200 20503582 19620834 10283819 9232479 2731612 4858572 238595505 223798085 72152705 101810267 0 0 57146058 70340964 1388063 2370683 32475374 32202373 41238028 162889199 215759942 75706306 8038143 389461665 446188087 94551427 139007857 294910238 307180230 X SEE SCHEDULE O. 0 0 101810267 101810267 RESEARCH FUNDING - FOR THE YEAR ENDED JUNE 30, 2023, JDRF DIRECTLY FUNDED RESEARCH GRANTS AND INDUSTRY AGREEMENTS FOR WHICH $98 MILLION IN RESEARCH GRANT EXPENSE, NET WAS RECOGNIZED ACCORDING TO GAAP IN ADDITION TO $20.5 MILLION OF PROGRAMMATIC RESEARCH INVESTMENTS THAT ARE RECORDED ON JDRF'S BALANCE SHEET. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO DIRECT RESEARCH FUNDING, SEE SCHEDULE O. 45534654 PUBLIC EDUCATION AND OUTREACH - JDRF EDUCATES THE COMMUNITY AND PROVIDES OUTREACH SERVICES TO NEWLY DIAGNOSED CHILDREN AND ADULTS, THEIR FAMILIES, AND OTHERS ABOUT TYPE 1 DIABETES (T1D) AND ITS COMPLICATIONS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO PUBLIC EDUCATION AND OUTREACH, SEE SCHEDULE O. 19343713 RESEARCH SUPPORT - JDRF MAINTAINS AN IN-HOUSE TEAM OF SKILLED SCIENTIFIC, MEDICAL, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS WHO PLAY A CRITICAL ROLE IN LEADING AND SUPPORTING THE EVALUATION OF RESEARCH FUNDING OPPORTUNITIES BY JDRF AND INFLUENCING RESEARCH DIRECTION AND THE DISBURSEMENT OF RESEARCH FUNDS FROM OTHERS. THESE PROFESSIONALS ALSO WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE THAT RESEARCH CAN PROCEED WITHOUT DELAY AND RESULTS ARE UNDERSTOOD BY HEALTHCARE DECISION MAKERS. FOR AN EXPANDED DESCRIPTION OF PROGRAM SERVICE ACTIVITIES RELATED TO RESEARCH SUPPORT, SEE SCHEDULE O. 166688634 1 1 0 1 0 0 0 0 0 1 1 0 1 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 1 582 2 1 570 1 1 1 0 0 0 0 1 1 0 0 0 1 0 0 0 X 16 15 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VT VA WA WV WI WY X X ROBERT KING 8005332873 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 GRANT BEARD CHAIR OF THE BOARD 5.00 0.00 X X 0 0 0 MICHELLE GRIFFIN VICE CHAIR OF THE BOARD (BEG 7/22) 5.00 0.00 X X 0 0 0 MICHAEL ALTER CHAIR, FUNDING COMMITTEE 5.00 0.00 X 0 0 0 ELIZABETH CASWELL BOARD MEMBER 3.00 0.00 X 0 0 0 STEVEN DAVIS BOARD MEMBER 3.00 0.00 X 0 0 0 CLAUDIA GRAHAM PHD CHAIR, ADVOCACY & IMPACT COMMITTEE 5.00 0.00 X 0 0 0 PAUL HEATH BOARD MEMBER 3.00 0.00 X 0 0 0 KAREN JORDAN CHAIR, RESEARCH COMMITTEE 5.00 0.00 X 0 0 0 JOE LACHER BOARD MEMBER 3.00 0.00 X 0 0 0 JEFF PLUMER CHAIR, TALENT & COMP COMMITTEE 5.00 0.00 X 0 0 0 JENNIFER SCHNEIDER MD CHAIR, NOMINATING & GOV COMMITTEE 5.00 0.00 X 0 0 0 CHRISTOPHER TURNER CHAIR, FINANCE & INVEST COMMITTEE 5.00 0.00 X 0 0 0 MATT VAREY CHAIR, AUDIT & RISK COMMITTEE 5.00 0.00 X 0 0 0 DRAYTON VIRKLER BOARD MEMBER 3.00 0.00 X 0 0 0 LISA WALLACK BOARD MEMBER 3.00 0.00 X 0 0 0 KAREY L WITTY BOARD MEMBER 3.00 0.00 X 0 0 0 AARON KOWALSKI PHD CHIEF EXECUTIVE OFFICER 50.00 0.00 X 824920 0 54692 TIMOTHY DOYLE COO/PRESIDENT/ASST TREAS (END 11/22) 50.00 0.00 X 623521 0 63733 ROBERT KING CFAO/TREASURER 50.00 0.00 X 426077 0 26603 SYDNEY YOVIC CHF. STRATEGY OFC/CHF. OF STAFF 50.00 0.00 X 283558 0 49170 JAMES MCDONALD BOARD LIAISON/SECRETARY 50.00 0.00 X 130725 0 5615 STEVEN ST PETER MANAGING DIRECTOR, T1D FUND 50.00 0.00 X 700527 0 33224 HELEN ELLIAS MANAGING DIRECTOR, T1D FUND 50.00 0.00 X 545786 0 13126 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 50.00 0.00 X 393469 0 3949 MIMI CRABTREE EXECUTIVE DIRECTOR, GREATER NY CHAPTER 50.00 0.00 X 307483 0 25499 CYNTHIA RICE CHIEF MISSION OFFICER 50.00 0.00 X 400987 0 34506 PAMELA MORRISROE CHIEF MARKETING OFFICER 50.00 0.00 X 439408 0 36621 TRACY MIDO CHIEF HUMAN RESOURCES OFFICER 50.00 0.00 X 350622 0 6363 YURY KUKUSHKIN MANAGING DIRECTOR, T1D FUND 50.00 0.00 X 324200 0 8354 TROY LINDLOFF FORMER OFFICER 50.00 0.00 X 405125 0 0 JOANNE MARTZ FORMER OFFICER 50.00 0.00 X 110769 0 0 6267177 0 361455 159 1 1 0 INNOVATION CLOUD LLC 356 OSWEGO CT WEST NEW YORK NY 07093 IT CONSULTING 2539664 CENTRIC CONSULTING LLC PO BOX 75581 CLEVELAND OH 44104 IT CONSULTING 652660 BEYOND TECHNOLOGIES LLC 201 N ILLINOIS ST 16TH FLOOR INDIANAPOLIS IN 46204 IT CONSULTING 593830 COMMUNITY COUNSELING SERVICE CO LLC 527 MADISON AVE 5TH FLOOR NEW YORK NY 10022 FUNDRAISING CONSULTING 539974 STANTON BLACKWELL PO BOX 7024 EVANSTON IL 60204 PROJECT MANAGEMENT 435985 28 3294487 102388737 84402976 10223200 190086200 PROGRAM RELATED INVEST 541714 19620834 19620834 19620834 7848897 46542 7802355 155220 155220 54122 0 54122 54122 54122 103293947 101910365 1383582 1383582 1383582 25328970 102388737 25328970 0 0 825131 24748 800383 800383 GRANT REFUNDS & ADJUST 813212 3694186 3694186 MISC REVENUE 900099 154661 154661 3848847 223798085 0 46542 33665343 74336017 74336017 27474250 27474250 4303720 2897410 1023154 383156 75818 44808 9553 21457 52321178 30212786 7518428 14589964 1673709 963421 239345 470943 8404956 4689515 1293578 2421863 3561583 2060496 525483 975604 511286 332819 80469 97998 273000 273000 518889 518889 2370683 2370683 564894 564894 6126193 3819749 1213449 1092995 3500633 1956952 331413 1212268 843646 474377 118086 251183 6656266 3856489 1018782 1780995 4907753 2896042 681434 1330277 2567798 1627930 188474 751394 1290693 599597 97516 593580 4009 2948 325 736 6182809 3600532 931499 1650778 562488 241728 196704 124056 OUTREACH EXPENSES 4644608 3640160 161069 843379 FUNDR. POSTAGE & PRINT 1309879 1309879 DUES, FEES, & SUB 715226 421075 101851 192300 57958 20644 27428 9886 215759942 166688634 16595934 32475374 X 4318548 1079637 0 3238911 34312094 11494106 4006288 1606788 56535885 50188103 2438959 2859833 2218711 6689096 15358433 10110542 31059383 20980433 10571069 10078950 212935519 270968509 533309 393344 50551398 63438834 0 18359982 389461665 446188087 17575122 13191296 69409827 96425875 5150523 6416162 2415955 22974524 94551427 139007857 X 229545554 247180317 65364684 59999913 294910238 307180230 389461665 446188087 8038143 4231849 0 X 0 1 X 1 0 X 215659011 194074339 190647071 203302047 189472784 993155252 215659011 194074339 190647071 203302047 189472784 993155252 993155252 2438175 2918738 2297884 2679458 8011697 18345952 186965 29579 58494 72762 23845 371645 2313482 1671720 3345522 22507054 23469681 53307459 1065180308 0.93240 0.95830 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: PROGRAM RELATED INVESTMENT OTHER EXCLUDED INCOME - 2018 AMOUNT: $ 2,313,482. 2019 AMOUNT: $ 1,671,720. 2020 AMOUNT: $ 3,345,522. 2021 AMOUNT: $ 22,507,054. 2022 AMOUNT: $ 23,469,681. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 0 0 1 39811 0 1 7675 1 635324 0 1 54942 737752 0 PART II-B, LINE 1: GENERAL STATEMENT OF ACTIVITIES JDRF IS THE LEADING GLOBAL ORGANIZATION FUNDING TYPE 1 DIABETES (T1D) RESEARCH, FOCUSED ON CURING T1D AND IMPROVING LIVES. JDRF'S ADVOCACY INCLUDES NON-PARTISAN LOBBYING ACTIVITY TO ENSURE CONGRESS CONTINUES TO INVEST IN CRITICALLY IMPORTANT MEDICAL RESEARCH AND PUTS IN PLACE POLICIES TO ADVANCE DEVELOPMENT AND ACCESS TO THERAPIES TO CURE T1D AND HELP PEOPLE STAY AS HEALTHY AS POSSIBLE UNTIL THAT DAY. JDRF HAS BEEN INSTRUMENTAL IN SECURING THE RENEWAL OF THE SPECIAL DIABETES PROGRAM, WHICH PROVIDES $150M ANNUALLY FOR T1D RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH. JDRF STAFF AND VOLUNTEERS COMMUNICATE WITH GOVERNMENT OFFICIALS THROUGH EMAIL, PHONE CALLS, AND MEETINGS, TO EDUCATE THEM ON ISSUES AND ENCOURAGE THE ADVANCEMENT OF LEGISLATION. FY23 LOBBYING ACTIVITIES DO NOT REPRESENT A SUBSTANTIAL PART OF THE ORGANIZATION'S OVERALL ACTIVITIES. 7584083 503698 215224 7872557 8911983 25000 -1144983 207917 7584083 7709169 2111094 908280 8911983 7887833 -140727 33086 71023 7709169 7567601 221441 102034 3243 7887833 0.00000 1.00000 0.00000 0 0 2671357 466662 2204695 28388026 20513771 7874255 10078950 T1D FUND PROGRAM RELATED INVESTMENTS 63438834 F 63438834 LIABILITIES RELATED TO SPLIT-INTEREST AGREEMENTS 2393198 OPERATING & FINANCE LEASE LIABILITY 20581326 22974524 X 224378712 4231849 607858 4839707 219539005 564894 3694186 4259080 223798085 212108719 607857 -3694186 -3086329 215195048 564894 564894 215759942 PART V, LINE 4: ORGANIZATION'S ENDOWMENT FUNDS THE ORGANIZATION UTILIZES EARNINGS ON ENDOWMENT FUNDS IN THE MANNER SPECIFIED BY THE DONOR AND/OR FOR SUPPORTING THE ORGANIZATION'S GENERAL EXEMPT PURPOSE. PART X, LINE 2: UNCERTAIN TAX POSITIONS JDRF IS A NOT-FOR-PROFIT ORGANIZATION EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA. THE EFFECT OF INCOME TAX POSITIONS IS RECOGNIZED ONLY IF THE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO JDRF'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. JDRF'S UNRELATED BUSINESS INCOME TAX LIABILITY WAS INSIGNIFICANT FOR THE YEARS ENDING JUNE 30, 2023 AND 2022. PART XI, LINE 4B - OTHER ADJUSTMENTS: GRANT REFUNDS & ADJUSTMENTS 3,694,186. 1 EAST ASIA AND THE PACIFIC GRANTMAKING RESEARCH GRANTS 3784197 NORTH AMERICA GRANTMAKING RESEARCH GRANTS 3611857 EUROPE GRANTMAKING RESEARCH GRANTS 16438714 MIDDLE EAST AND NORTH AFRICA GRANTMAKING RESEARCH GRANTS 3354410 SOUTH ASIA GRANTMAKING RESEARCH GRANTS 285072 EUROPE 2 PROGRAM SERVICES RESEARCH SUPPORT 359258 NORTH AMERICA INVESTMENTS INVESTMENTS 16741742 EUROPE INVESTMENTS INVESTMENTS 7829760 0 2 0 0 0 2 52405010 0 52405010 NORTH AMERICA BETA CELL REPLACEMENT 100000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 1455871 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA PREVENTION 299985 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) TRANSPORTFOLIO 55580 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 186430 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA BETA CELL REPLACEMENT 449936 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 1224862 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 147950 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 126500 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 499460 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) TRANSPORTFOLIO 290000 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA TRANSPORTFOLIO 500000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 725958 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 326083 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) METABOLIC CONTROL 533327 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA ARTIFICIAL PANCREAS 267947 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 124834 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC IMMUNOTHERAPIES 225000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC IMMUNOTHERAPIES 170000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC IMMUNOTHERAPIES 100000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 947383 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 232616 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA ARTIFICIAL PANCREAS 156936 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA PREVENTION 1897538 CHECK/WIRE TRANSFER 0 N/A N/A MIDDLE EAST AND NORTH AFRICA PREVENTION 350000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 374732 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC BETA CELL REPLACEMENT 885639 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PSYCHOSOCIAL 896274 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REGENERATION 300000 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 474881 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 699541 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC PREVENTION 892870 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REPLACEMENT 648252 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 582056 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 62958 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REPLACEMENT 705851 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 750857 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 123080 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC PREVENTION 200000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 700000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REPLACEMENT 63128 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA ARTIFICIAL PANCREAS 451920 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 399851 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC PREVENTION 367134 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) ARTIFICIAL PANCREAS 50000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC METABOLIC CONTROL 363963 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REPLACEMENT 80000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PSYCHOSOCIAL 611505 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) COMPLICATIONS 300000 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC ARTIFICIAL PANCREAS 302685 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 245573 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 500000 CHECK/WIRE TRANSFER 0 N/A N/A SOUTH ASIA ARTIFICIAL PANCREAS 285072 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 245354 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) COMPLICATIONS 216019 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 613581 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REGENERATION 170000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 143289 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PSYCHOSOCIAL 45879 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PSYCHOSOCIAL 109958 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA BETA CELL REGENERATION 299894 CHECK/WIRE TRANSFER 0 N/A N/A EAST ASIA AND THE PACIFIC PSYCHOSOCIAL 276907 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) PREVENTION 176591 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) COMPLICATIONS 695616 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) BETA CELL REPLACEMENT 180550 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 70000 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) IMMUNOTHERAPIES 199972 CHECK/WIRE TRANSFER 0 N/A N/A EUROPE (INCLUDING ICELAND AND GREENLAND) METABOLIC CONTROL 118624 CHECK/WIRE TRANSFER 0 N/A N/A NORTH AMERICA METABOLIC CONTROL 200000 CHECK/WIRE TRANSFER 0 N/A N/A 0 69 1 0 1 0 0 1 PART I, LINE 2: GRANT MONITORING PROCEDURES RESEARCH GRANTS ARE AWARDED BY JDRF INTERNATIONAL ("JDRFI") WITH THE SUPPORT OF JDRFI'S RESEARCH COMMITTEE COMPRISED OF "JDRFI BOARD MEMBERS AND OTHER VOLUNTEERS" FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO JDRF'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. PART III ACCOUNTING METHOD: PART II, LINES 2 AND 3: WHILE MANY FOREIGN GRANTEES MAY BE RECOGNIZED AS CHARITIES IN THEIR RESPECTIVE COUNTRY OR AS 501(C)(3) ORGANIZATIONS BY THE IRS, JDRF DOES NOT HAVE A FEASIBLE WAY TO VALIDATE FOREIGN TAX EXEMPTION AND CONSERVATIVELY CLASSIFIES ALL FOREIGN GRANTEES AS OTHER. X X X X X X 1 BLUE STATE DIGITAL 41 FLATBUSH AVENUE 8TH FL BROOKLYN NY 11217 DIRECT APPEAL FUNDRAISING SERVICES 0 4294870 482366 3812504 THE PURSUANT GROUP 15660 NORTH DALLAS PARKWAY SUITE 1 DALLAS TX 75248 DIRECT APPEAL FUNDRAISING SERVICES 0 2462500 696101 1766399 CHARITABLE ADULT RIDES & SERVICES INC (CARS) 4669 MURPHY CANYON RD 200 SAN DIEGO CA 92123 CAR DONATIONS 1 195825 54124 141701 CASWELL ZACHRY GRIZZARD 6301 GASTON AVENUE SUITE 715 DALLAS TX 75214 PLANNED GIVING MARKETING 0 0 199999 -199999 COMMUNITY COUNSELING SERVICE CO LLC 527 MADISON AVE 5TH FLOOR NEW YORK NY 10022 COMPREHENSIVE CAMPAIGN ADVISORY SERVICES 0 0 906333 -906333 SYNERGY DIRECT MARKETING SOLUTIONS LLC 480 WEST TUSCARAWAS AVE SUITE 307 BARBERTON OH 44203 TEXT MESSAGING CAMPAIGN 0 0 31760 -31760 6953195 2370683 4582512 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI ILLINOIS GALA 16091205 14964436 1126769 129974 424412 432942 139442 PNW DREAM GALA 3686783 2956253 730530 256962 3743 243977 225847 288 107939719 84468048 23471671 3650204 4353025 5571021 9897421 127717707 102388737 25328970 4037140 4781180 6247940 10262710 25328970 0 825131 24748 0 0 825131 24748 24748 800383 AL AK AZ CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI 1 0 0 0 1.00000 KIMBERLY ZINGALE MANAGER FINANCIAL REPORTING AND COMPLIANCE - JDRF 200 VESEY STREET 28TH FLOOR NEW YORK NY 10281 0 ROBERT KING CFO - JDRF FILING GAMING APPLICATIONS AND REPORTS X 0 PART I, LINE 2: CHARITABLE ADULT RIDES AND SERVICES (CARS) IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, CARS HANDLES ALL IRS 1098-C REPORTING. FOR THE YEAR ENDED 6/30/2023, CARS RAISED $195,825, WITH SELLING EXPENSES OF $18,726 AND FUNDRAISING SERVICE FEES OF $35,398. JDRF DOES NOT PAY CARS ANY EXPENSES OR FEES DIRECTLY. JDRF RECEIVED $141,701 OF NET REVENUE FROM CARS IN FY 2023. PART I, LINE 2: SEPARATE FROM PROFESSIONAL FUNDRAISING SERVICES REPORTED ON SCHEDULE G, PART I, JDRF PAID FUNDRAISING EXPENSES OF $382,621 FOR POSTAGE AND $902,261 FOR PRINTING TO THE PURSUANT GROUP. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. PART I, LINE 2: SEPARATE FROM PROFESSIONAL FUNDRAISING SERVICES REPORTED ON SCHEDULE G, PART I, JDRF PAID FUNDRAISING EXPENSES OF $24,997 FOR POSTAGE TO CASWELL. THE INVOICES PROVIDE AN ITEMIZED LIST OF SERVICES AND EXPENSES. 1 ADVANCED REGENERATIVE MANUFACTURING INSTITUTE (ARMI) 400 COMMERCIAL STREET MANCHESTER NH 03101 813327581 501(C)(6) 823255 0 N/A N/A BETA CELL REPLACEMENT ADVENTHEALTH 601 EAST ROLLINS ST PO BOX 37 ORLANDO FL 328031248 590724459 501(C)(3) 310840 0 N/A N/A PREVENTION ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 830621846 501(C)(3) 737989 0 N/A N/A PSYCHOSOCIAL ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO 225 EAST CHICAGO AVE PO BOX 10 CHICAGO IL 60611 362170833 501(C)(3) 223981 0 N/A N/A PSYCHOSOCIAL ARIZONA BOARD OF REGENTS UNIVERSITY OF ARIZONA PO BOX 210158 TUCSON AZ 857210158 742652689 501(C)(3) 783788 0 N/A N/A BETA CELL REPLACEMENT AVERA MCKENNAN 1325 S CLIFF AVE SIOUX FALLS SD 57108 301043916 501(C)(3) 1520870 0 N/A N/A PSYCHOSOCIAL BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 501(C)(3) 64999 0 N/A N/A PSYCHOSOCIAL BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 E DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 2559923 0 N/A N/A BETA CELL REGENERATION BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON 1201 NINTH AVENUE - NA SEATTLE CA 981012795 910653422 501(C)(3) 62550 0 N/A N/A IMMUNOTHERAPIES BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA 4225-H OCEANSIDE BOULEVARD 273 OCEANSIDE CA 92056 452210161 501(C)(3) 200000 0 N/A N/A IMMUNOTHERAPIES BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02215 042774441 501(C)(3) 800000 0 N/A N/A BETA CELL REPLACEMENT BRIGHAM AND WOMEN'S HOSPITAL INC 75 FRANCIS ST BOSTON MA 02115 042312909 501(C)(3) 750000 0 N/A N/A BETA CELL REGENERATION BROWN UNIVERSITY 164 ANGELL ST PO BOX 1929 PROVIDENCE RI 02912 050258809 501(C)(3) 515823 0 N/A N/A BETA CELL REPLACEMENT CALIFORNIA INSTITUTE OF TECHNOLOGY 1200 E CALIFORNIA BLVD MAIL CODE 234-6 PASADENA CA 91125 951643307 501(C)(3) 250000 0 N/A N/A BETA CELL REPLACEMENT CARNEGIE MELLON UNIVERSITY PO BOX 371032 PITTSBURGH PA 15213 250969449 501(C)(3) 297081 0 N/A N/A PSYCHOSOCIAL CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVE STE 357 CLEVELAND OH 441063052 341018992 501(C)(3) 200000 0 N/A N/A IMMUNOTHERAPIES CHILDREN'S HOSPITAL OF PHILADELPHIA LOCKBOX 1457 PO BOX 8500 PHILADELPHIA PA 191781457 231352166 501(C)(3) 149998 0 N/A N/A PREVENTION CHILDREN'S MERCY HOSPITAL 2401 GILLHAM ROAD KANSAS CITY MO 64108 440605373 501(C)(3) 473623 0 N/A N/A PSYCHOSOCIAL CIVICA RX 2912 W EXECUTIVE PKWY STE 325 LEHI UT 840434622 844514428 501(C)(3) 3000000 0 N/A N/A MISSION COLORADO SCHOOL OF MINES 1500 ILLINOIS ST GOLDEN CO 80401 846000551 501(C)(3) 300000 0 N/A N/A BETA CELL REGENERATION CORNELL UNIVERSITY 377 PINE TREE RD ITHACA NY 148502820 150532082 501(C)(3) 200000 0 N/A N/A ARTIFICIAL PANCREAS CRITICAL PATH INSTITUTE (C-PATH) 1730 EAST RIVER ROAD 200 TUCSON AZ 85718 201999134 501(C)(3) 1021906 0 N/A N/A IMMUNOTHERAPIES DIATECH DIABETES INC 88 UNION AVE MEMPHIS TN 38103 841890342 N/A 100000 0 N/A N/A ARTIFICIAL PANCREAS DUKE UNIVERSITY PO BOX 602651 CHARLOTTE NC 282602651 560532129 501(C)(3) 527983 0 N/A N/A PSYCHOSOCIAL EVOQ THERAPEUTICS INC 1600 HURON PARKWAY BLG 520 2ND FL ANN ARBOR MI 48109 813291966 N/A 165000 0 N/A N/A IMMUNOTHERAPIES GEISINGER CLINIC 100 N ACADEMY AVE DANVILLE PA 178223057 236291113 501(C)(3) 648325 0 N/A N/A PREVENTION GEORGIA SOUTHERN UNIVERSITY RESEARCH AND SERVICE FOUNDATION INC 261 FOREST DRIVE STATESBORO GA 30458 582354256 501(C)(3) 199517 0 N/A N/A ARTIFICIAL PANCREAS GEORGIA TECH RESEARCH CORPORATION PO BOX 100117 ATLANTA GA 30384 580603146 501(C)(3) 224166 0 N/A N/A BETA CELL REPLACEMENT GINER INC 89 RUMFORD AVE NEWTON MA 02466 821416958 N/A 39968 0 N/A N/A BETA CELL REPLACEMENT HUMACYTE 2525 E NC HWY 54 STE 104 DURHAM NC 27713 841661297 N/A 80000 0 N/A N/A BETA CELL REPLACEMENT ILLINOIS INSTITUTE OF TECHNOLOGY 3424 S STATE STSTE TC-4TH FL RM 4C8-2 CHICAGO IL 606163717 362170136 501(C)(3) 94834 0 N/A N/A ARTIFICIAL PANCREAS INDIANA BIOSCIENCES RESEARCH INSTITUTE 1210 WATERWAY BLVD STE 2000 INDIANAPOLIS IN 46202 462882271 501(C)(3) 544959 0 N/A N/A BETA CELL REGENERATION INDIANA UNIVERSITY OFFICE OF RESEARCH ADMIN DEPT 78867 PO BOX 78000 DETROIT MI 482780867 356001673 501(C)(3) 919800 0 N/A N/A BETA CELL REGENERATION INTEGRATED MEDICAL SENSORS INC 30 HUGHES SUITE 200 IRVINE CA 92618 474751319 N/A 140000 0 N/A N/A ARTIFICIAL PANCREAS IQVIA INC 100 IMS DRIVE PARSIPPANY NJ 07054 271341991 N/A 1260738 0 N/A N/A PREVENTION ITOLERANCE INC 1221 SHAFTER STREET SAN MATEO CA 94402 853086959 N/A 85000 0 N/A N/A BETA CELL REPLACEMENT IVIVA MEDICAL INC 100 CUMMINGS CENTER STE 451C BEVERLY MA 01915 320423382 501(C)(3) 37500 0 N/A N/A BETA CELL REPLACEMENT JAEB CENTER FOR HEALTH RESEARCH 15310 AMBERLY DRIVE STE 350 TAMPA FL 33647 593187624 501(C)(3) 458402 0 N/A N/A PREVENTION JOHNS HOPKINS UNIVERSITY 733 N BROADWAY 600 N WOLFE ST BALTIMORE MD 21205 520595110 501(C)(3) 866182 0 N/A N/A IMMUNOTHERAPIES JOSLIN DIABETES CENTER INC ONE JOSLIN PLACE BOSTON MA 022155306 042203836 501(C)(3) 1033906 0 N/A N/A COMPLICATIONS LIEBERMAN RESEARCH 98 CUTTER MILL RD STE 359 GREAT NECK PLAZA NY 110213036 112576076 N/A 46000 0 N/A N/A TRANSPORTFOLIO MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 021144876 042697983 501(C)(3) 771083 0 N/A N/A IMMUNOTHERAPIES MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 559050001 416011702 501(C)(3) 200000 0 N/A N/A BETA CELL REGENERATION MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE BOX 701 NEW YORK NY 10065 131924236 501(C)(3) 449983 0 N/A N/A BETA CELL REPLACEMENT MICHIGAN STATE UNIVERSITY 426 AUDITORIUM RD RM 2 EAST LANSING MI 488242613 386005984 501(C)(3) 250000 0 N/A N/A BETA CELL REPLACEMENT MINUTIA 535 BELLEVUE AVE UNIT 8 OAKLAND CA 94610 851020286 N/A 237150 0 N/A N/A BETA CELL REPLACEMENT NEMOURS CHILDREN'S CLINIC 10140 CENTURION PARKWAY NORTH JACKSONVILLE FL 32256 590634433 501(C)(3) 200744 0 N/A N/A PSYCHOSOCIAL NEURODON LLC 9800 CONNECTICUT DRIVE CROWN POINT IN 46307 465375254 N/A 119600 0 N/A N/A BETA CELL REGENERATION NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE RD ADMIN BLDG VALHALLA NY 10595 131099420 501(C)(3) 250000 0 N/A N/A BETA CELL REGENERATION NEW YORK STEM CELL FOUNDATION INC 619 WEST 54TH STREET 3RD FLOOR NEW YORK NY 10019 202905531 501(C)(3) 100000 0 N/A N/A IMMUNOTHERAPIES NORTHWESTERN UNIVERSITY 633 CLARK ST ROOM G-547 CROWN EVANSTON IL 60208 362167817 501(C)(3) 577659 0 N/A N/A IMMUNOTHERAPIES OREGON HEALTH & SCIENCE UNIVERSITY 0690 SW BANCROFT STREET L106SPA PORTLAND OR 97239 931176109 501(C)(3) 199765 0 N/A N/A ARTIFICIAL PANCREAS PHYSIOLOGIC DEVICES INC 2232 OLD STAGECOACH TRAIL ALPINE CA 91901 800917839 N/A 53000 0 N/A N/A ARTIFICIAL PANCREAS PRESIDENT AND FELLOWS OF HARVARD COLLEGE P O BOX 415649 BOSTON MA 022415649 042103580 501(C)(3) 295000 0 N/A N/A IMMUNOTHERAPIES PUTNAM ASSOCIATES 501 BOYLSTON STREET BOSTON MA 02116 463321955 501(C)(3) 328700 0 N/A N/A IMMUNOTHERAPIES RECTOR & VISITORS OF THE UNIVERSITY OF VIRGINIA PO BOX 400195 OFFICE OF SPONSORED PROGRAMS CHARLOTTESVILLE VA 229044195 546001796 501(C)(3) 1149233 0 N/A N/A BETA CELL REPLACEMENT REGENTS OF THE UNIVERSITY OF COLORADO GRANTS AND CONTRACTS 10-2011-138-GE MAIL STOP F428 DEP 238 DENVER CO 802910238 846000555 501(C)(3) 5657381 0 N/A N/A IMMUNOTHERAPIES REGENTS OF THE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE ST RM 1054 ANN ARBOR MI 48109 386006309 501(C)(3) 2239313 0 N/A N/A COMPLICATIONS REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 PO BOX 1450 MINNEAPOLIS MN 554855957 416007513 501(C)(3) 1222389 0 N/A N/A BETA CELL REGENERATION REMD BIOTHERAPEUTICS 4010 ADOLFO ROAD STE A CAMARILLO CA 93012 454614986 N/A 67000 0 N/A N/A METABOLIC CONTROL RTI INTERNATIONAL PO BOX 14668 RESEARCH TRIANGLE PARK NC 27709 560686338 501(C)(3) 1423552 0 N/A N/A TRANSPORTFOLIO RUTGERS BIOMEDICAL AND HEALTH SCIENCES 33 KNIGHTSBRIDGE RD 2ND FL EAST WING PISCATAWAY NJ 088543925 462354111 501(C)(3) 305918 0 N/A N/A IMMUNOTHERAPIES RUTGERS THE STATE UNIVERSITY OF NEW JERSEY 33 KNIGHTSBRIDGE ROAD 2ND FL EAST WING PISCATAWAY NJ 088543925 226001086 501(C)(3) 278166 0 N/A N/A PREVENTION SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 10901 NORTH TORREY PINES ROAD LA JOLLA CA 920371005 510197108 501(C)(3) 330000 0 N/A N/A BETA CELL REGENERATION STANFORD UNIVERSITY PO BOX 44253 SAN FRANCISCO CA 441444253 941156365 501(C)(3) 1330787 0 N/A N/A METABOLIC CONTROL T1D EXCHANGE INC 11 AVENUE DE LAFAYETTE 5TH FL BOSTON MA 02111 451623549 501(C)(3) 880015 0 N/A N/A PREVENTION THE LUNDQUIST INSTITUTE 1124 WEST CARSON ST TORRANCE CA 90502 952138184 501(C)(3) 149999 0 N/A N/A BETA CELL REPLACEMENT THE MEDICAL COLLEGE OF WISCONSIN INC 8701 WATERTOWN PLANK ROAD MILWAUKEE WI 53226 390806261 501(C)(3) 315683 0 N/A N/A IMMUNOTHERAPIES THE METHODIST HOSPITAL RESEARCH INSTITUTE 6670 BERTNER AVE HOUSTON TX 77030 870721923 501(C)(3) 430000 0 N/A N/A BETA CELL REPLACEMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 11000 KINROSS AVE 211PO BOX 951406 LOS ANGELES CA 900951406 956006143 501(C)(3) 461155 0 N/A N/A METABOLIC CONTROL THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST STE 425 BOX 0897 SAN FRANCISCO CA 94143 946036493 501(C)(3) 3520751 0 N/A N/A BETA CELL REPLACEMENT THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVE ADM BLDG RM 7 CHICAGO IL 60637 362177139 501(C)(3) 362232 0 N/A N/A BETA CELL REGENERATION THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT ROAD SUITE 2200 CHAPEL HILL NC 27707 566001393 501(C)(3) 400000 0 N/A N/A ARTIFICIAL PANCREAS TIDEPOOL 450 TOWNSEND ST SAN FRANCISCO CA 94107 462302287 501(C)(3) 750000 0 N/A N/A MISSION TORRAMICS INC 440 N BARRANCA AVE 2897 COVINA CA 91723 872652308 N/A 150000 0 N/A N/A ARTIFICIAL PANCREAS TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK PO BOX 29789 NEW YORK NY 100879789 135598093 501(C)(3) 349999 0 N/A N/A BETA CELL REPLACEMENT TRUSTEES OF INDIANA UNIVERSITY PO BOX 78000 DETROIT MI 482780867 356001673 501(C)(3) 280000 0 N/A N/A PREVENTION TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA P-221 FRANKLIN BLG 3451 WALNUT STREET PHILADELPHIA PA 191785541 231352685 501(C)(3) 338378 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF ALABAMA AT BIRMINGHAM 201 S PRESIDENTS CIRCLE RM 406 SALT LAKE CITY UT 841129020 636005396 501(C)(3) 749939 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DR LA JOLLA CA 920930009 956006144 501(C)(3) 1370846 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF CALIFORNIA SANTA BARBARA 1212 SAASB SANTA BARBARA CA 93106 956006145 501(C)(3) 527616 0 N/A N/A ARTIFICIAL PANCREAS UNIVERSITY OF CINCINNATI PO BOX 932641 CLEVELAND OH 441930014 316000989 501(C)(3) 250000 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF FLORIDA 123 GRINTER HALL PO BOX 113001 GAINESVILLE FL 326113001 596002052 501(C)(3) 3886548 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MSN 1039 KANSAS CITY KS 661032937 481108830 501(C)(3) 250000 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF MARYLAND 4101 CHESAPEAKE BLG 4300 TERRAPIN TRAIL COLLEGE PARK MD 207423141 526002033 501(C)(3) 329999 0 N/A N/A IMMUNOTHERAPIES UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVE NORTH WORCESTER MA 01655 043167352 501(C)(3) 7498644 0 N/A N/A BETA CELL REPLACEMENT UNIVERSITY OF MIAMI 1400 NW 10TH AVENUE 10TH FLOOR- MIAMI FL 33136 590624458 501(C)(3) 1848968 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF NOTRE DAME 836A GRACE HALL NOTRE DAME IN 46556 350868188 501(C)(3) 150000 0 N/A N/A METABOLIC CONTROL UNIVERSITY OF PITTSBURGH PO BOX 371220 PITTSBURGH PA 152517220 250965591 501(C)(3) 624395 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF TEXAS AT AUSTIN 3925 W BRAKER LN STE 3340 AUSTIN TX 78759 746000203 501(C)(3) 187620 0 N/A N/A PREVENTION UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE ROOM 406 SALT LAKE CITY UT 84112 876000525 501(C)(3) 463448 0 N/A N/A METABOLIC CONTROL UNIVERSITY OF WASHINGTON 3917 UNIVERSITY WAY NE SEATTLE WA 98195 916001537 501(C)(3) 1156640 0 N/A N/A BETA CELL REGENERATION UNIVERSITY OF WISCONSIN-MADISON UW-MADISON GAR ACCOUNT OFFICE DRAWER538 MILWAUKEE WI 532780538 396006492 501(C)(3) 1431376 0 N/A N/A COMPLICATIONS UT SOUTHWESTERN PO BOX 841753 DALLAS TX 752841753 752556007 501(C)(3) 913339 0 N/A N/A BETA CELL REPLACEMENT VANDERBILT UNIVERSITY MEDICAL CENTER (VUMC) DOF DEPT AT 40303 ATLANTA GA 31192 352528741 501(C)(3) 615000 0 N/A N/A IMMUNOTHERAPIES WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 271570001 223849199 501(C)(3) 249999 0 N/A N/A BETA CELL REPLACEMENT WASHINGTON UNIVERSITY CAMPUS BOX 1034-700 ROSEDALE AVE ST LOUIS MO 631121408 430653611 501(C)(3) 554944 0 N/A N/A BETA CELL REPLACEMENT WAYNE STATE UNIVERSITY 5057 WOODWARD AVE 13TH FL DETROIT MI 482024050 386028429 501(C)(3) 199231 0 N/A N/A BETA CELL REPLACEMENT WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE BOX 89 NEW YORK NY 10065 131623978 501(C)(3) 574986 0 N/A N/A BETA CELL REPLACEMENT WILLIAM MARSH RICE UNIVERSITY 6100 MAIN STREET - MS 16 HOUSTON TX 770051892 741109620 501(C)(3) 450000 0 N/A N/A BETA CELL REPLACEMENT YALE UNIVERSITY PO BOX 1873 - NA NEW HAVEN CT 065081873 060646973 501(C)(3) 908938 0 N/A N/A IMMUNOTHERAPIES 87 14 PART I, LINE 2: RESEARCH GRANTS ARE AWARDED BY JDRF INTERNATIONAL ("JDRFI") WITH THE SUPPORT OF JDRFI'S RESEARCH COMMITTEE COMPRISED OF "JDRF INTERNATIONAL BOARD MEMBERS AND OTHER VOLUNTEERS OR THE JDRF INTERNATIONAL BOARD OF DIRECTORS FOLLOWING THE RECOMMENDATIONS OF AN IN-HOUSE TEAM OF PROFESSIONAL SCIENTIFIC STAFF AND WITH INPUT FROM EXTERNAL SCIENTIFIC REVIEWERS. THE REVIEW PROCESS INCLUDES THE FOLLOWING CRITERIA: (1) THE SCIENTIFIC MERIT OF THE PROPOSED RESEARCH OUTLINED IN A GRANT APPLICATION AND (2) THE RELATIONSHIP OF THE PROPOSED RESEARCH TO JDRF'S GOAL TO IMPROVE LIVES TODAY AND TOMORROW BY ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, PREVENT AND TREAT T1D AND ITS COMPLICATIONS. THE SCIENTIFIC RESEARCH TEAM AND GRANT ADMINISTRATION STAFF MAINTAIN CLOSE CONTACT WITH GRANTEES, PROVIDING ADVICE AND EVALUATION, REVIEWING PROGRESS REPORTS, REVIEWING RESEARCH EXPENDITURES VERSUS AGREED BUDGETS, AND HELPING DISSEMINATE RESEARCH RESULTS. X X 1 0 X X X X X 1 0 0 0 0 0 0 1 0 AARON KOWALSKI PHD CHIEF EXECUTIVE OFFICER 524920 0 225000 0 75000 0 1266 0 53426 0 879612 0 0 0 STEVEN ST PETER MANAGING DIRECTOR, T1D FUND 400527 0 300000 0 0 0 9291 0 23933 0 733751 0 0 0 TIMOTHY DOYLE COO/PRESIDENT/ASST TREAS (END 11/22) 487368 0 97800 0 38353 0 10174 0 53559 0 687254 0 0 0 HELEN ELLIAS MANAGING DIRECTOR, T1D FUND 345786 0 200000 0 0 0 7710 0 5416 0 558912 0 0 0 PAMELA MORRISROE CHIEF MARKETING OFFICER 356608 0 82800 0 0 0 8224 0 28397 0 476029 0 0 0 ROBERT KING CFAO/TREASURER 359877 0 66200 0 0 0 7875 0 18728 0 452680 0 0 0 CYNTHIA RICE CHIEF MISSION OFFICER 334387 0 66600 0 0 0 7593 0 26913 0 435493 0 0 0 TROY LINDLOFF FORMER OFFICER 0 0 0 0 405125 0 0 0 0 0 405125 0 0 0 SANJOY DUTTA PHD CHIEF SCIENTIFIC OFFICER 329469 0 64000 0 0 0 0 0 3949 0 397418 0 0 0 TRACY MIDO CHIEF HUMAN RESOURCES OFFICER 293122 0 57500 0 0 0 3824 0 2539 0 356985 0 0 0 MIMI CRABTREE EXECUTIVE DIRECTOR, GREATER NY CHAPT 218291 0 47200 0 41992 0 4985 0 20514 0 332982 0 0 0 SYDNEY YOVIC CHF. STRATEGY OFC/CHF. OF STAFF 226358 0 57200 0 0 0 6591 0 42579 0 332728 0 0 0 YURY KUKUSHKIN MANAGING DIRECTOR, T1D FUND 245450 0 78750 0 0 0 5963 0 2391 0 332554 0 0 0 JOANNE MARTZ FORMER OFFICER 0 0 0 0 110769 0 0 0 0 0 110769 0 0 0 PART I, LINE 1A HOUSING ALLOWANCE CEO AARON KOWALSKI RECEIVED A TAXABLE HOUSING ALLOWANCE AS PER THE TERMS OF HIS EMPLOYMENT AGREEMENT. THE TOTAL FOR CALENDAR YEAR 2022 WAS $75,000. PART I, LINE 1A TAX INDEMNIFICATION AND GROSS-UP PAYMENTS MIMI CRABTREE, EXECUTIVE DIRECTOR, GREATER NEW YORK CITY CHAPTER, RECEIVED A TAXABLE GROSS-UP PAYMENT OF $41,992 FOR CALENDAR YEAR 2022. PART I, LINE 4A SEVERANCE PAYMENTS JOANNE MARTZ, TROY LINDLOFF AND TIMOTHY DOYLE RECEIVED SEVERANCE PAYMENTS AS PER THE TERMS OF THEIR EMPLOYMENT AGREEMENTS. THE TOTALS ARE AS FOLLOWS: JOANNE MARTZ - $110,769 TROY LINDLOFF - $405,125 TIMOTHY DOYLE - $38,353 SEVERANCE PAYMENTS ARE REPORTED ON SCHEDULE J, PART II, COLUMN (B)(III) AS OTHER REPORTABLE COMPENSATION. PART I, LINE 7 NON-FIXED PAYMENTS JDRF AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEES' PERFORMANCE. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COLUMN (B) (II). E BEARD SEE BELOW 75818 SEE BELOW 0 SCHEDULE L, PART IV, LINE 1 (B) E. BEARD HAS A FAMILY RELATIONSHIP WITH GRANT BEARD, A MEMBER OF JDRF'S BOARD OF DIRECTORS.(D) EMPLOYMENT BY JDRF. X 99 141701 NET PROCEEDS OF SALE X 209 10078239 NET PROCEEDS OF SALE X 1 3260 PER-SHARE EXERCISE PRICE 1 0 1 1 SCHEDULE M, PART I, LINE 32B THIRD PARTY ASSISTANCE CHARITABLE ADULT RIDES AND SERVICES (CARS) IS A THIRD PARTY CAR DONATION COMPANY THAT HANDLES ALL ASPECTS OF CARS BEING DONATED TO JDRF. DONORS CALL A TOLL FREE NUMBER AND ARE PUT IN CONTACT WITH A TOWING SERVICE IN THEIR AREA. AFTER THE CAR IS DONATED, CARS HANDLES ALL IRS 1098-C REPORTING. FOR THE YEAR ENDED 6/30/2023, CARS RAISED $195,825, WITH SELLING EXPENSES OF $18,726 AND FUNDRAISING SERVICE FEES OF $35,398. JDRF DOES NOT PAY CARS ANY EXPENSES OR FEES DIRECTLY. JDRF RECEIVED $141,701 OF NET REVENUE FROM CARS IN FY 2023. SCHEDULE M, PAGE 1 PART I, LINE 9 REPORTS THE NUMBER OF CONTRIBUTIONS OF SECURITIES THAT WERE MADE TO JDRF. FORM 990, PART I, LINE 1 AND PART III, LINE 1 - ORGANIZATION'S MISSION AT JDRF, WE WORK TIRELESSLY TO ACCELERATE BREAKTHROUGHS TO CURE, PREVENT AND TREAT TYPE 1 DIABETES (T1D). WE CONTINUALLY EXPAND OUR SCIENTIFIC KNOWLEDGE, OUR CONNECTIONS AND COLLABORATIONS, OUR PARTNERS AND GLOBAL PRESENCE TO UNLOCK THE SCIENCE THAT WILL STOP T1D. WHILE WE FIGHT FOR A CURE, WE STRIVE JUST AS HARD TO DEVELOP THERAPIES TO HELP PEOPLE RIGHT NOW. JDRF AND OUR SCIENTISTS ARE LEADING T1D RESEARCH AROUND THE WORLD. WE ADDRESS KEY GAPS TO MOVE RESEARCH FASTER AND FARTHER ACROSS THE DEVELOPMENT PIPELINE AND TO TRANSLATE BREAKTHROUGHS INTO NEW THERAPIES FOR PEOPLE WITH T1D. THIS ENABLES US TO ADVANCE SCIENCE WITH THE MOST POTENTIAL AND TO DRIVE RESEARCH THAT ATTRACTS MORE RESOURCES AND SCIENTIFIC EXPERTISE TO THE FIELD. WE INVEST IN THE EARLY STAGES, ALLOWING RESEARCHERS TO PURSUE INNOVATIVE IDEAS AND APPROACHES THAT WILL LEAD TO BREAKTHROUGH TREATMENTS. JDRF ALSO WORKS TO DRIVE NEW THERAPIES AND TECHNOLOGIES TO MARKET SO THEY GET INTO THE HANDS OF PEOPLE WITH T1D MORE QUICKLY. AND WE CONNECT THE T1D COMMUNITY TO CREATE A GLOBAL COMMUNITY OF SUPPORT FOR ANYONE AFFECTED BY T1D. FROM FUNDING INNOVATIVE RESEARCH TO ADVOCATING FOR GOVERNMENT ACTION AND PROVIDING A SUPPORT STRUCTURE FOR OUR COMMUNITY, NO OTHER ORGANIZATION DOES MORE TO FIGHT T1D THAN JDRF. SINCE OUR FOUNDING, JDRF HAS FUNDED MORE THAN $2.5 BILLION IN RESEARCH AND HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING AND FIGHTING THE DISEASE. OUR ACTIONS - THROUGH ADVOCACY AND OUR OWN INVESTMENTS IN T1D RESEARCH - INFLUENCE OTHER ORGANIZATIONS, CORPORATIONS AND GOVERNMENT AGENCIES TO FOLLOW OUR LEAD AND DIRECT ADDITIONAL FUNDING TOWARD T1D RESEARCH. TODAY, EVERY $1 JDRF INVESTS IN RESEARCH ATTRACTS AN ADDITIONAL $2.25 TO THE FIELD. FOR FISCAL YEAR 2023, JDRF'S APPROXIMATELY $138.4 MILLION IN DIRECT FUNDING ATTRACTED $311 MILLION IN ADDITIONAL INVESTMENT IN T1D RESEARCH FROM U.S. AND INTERNATIONAL GOVERNMENT, NGOS AND CHARITABLE ORGANIZATIONS, AND CORPORATE PARTNERS. FORM 990, PART III, LINE 4A: RESEARCH GRANTS JDRF HAS PLAYED A SIGNIFICANT ROLE IN NEARLY EVERY T1D ADVANCE--DRUG, DEVICE, CELL THERAPY--MADE IN THE LAST 50 YEARS. OUR FUNDING SUPPORTS MORE THAN 400 ACTIVE T1D RESEARCH GRANTS IN THE UNITED STATES AND 20+ OTHER COUNTRIES AROUND THE WORLD, INCLUDING 159 GRANTS IN FY2023 ALONE, PLUS 78 CLINICAL TRIALS. WE LEVERAGE PARTNERSHIPS WITH ACADEMIA, INDUSTRY, AND CLINICIANS TO ACCELERATE THE MOST PROMISING RESEARCH OPPORTUNITIES. OUR HIGHEST PRIORITY IS DEVELOPING CURES FOR T1D AND IMPROVING LIVES OF THOSE LIVING WITH THE DISEASE TODAY, INCLUDING RESEARCH IN GLUCOSE CONTROL AND PREVENTION OF T1D COMPLICATIONS. THE FULL IMPACT OF JDRF'S RESEARCH INVESTMENT EXTENDS WELL BEYOND DIRECT FUNDING. THROUGH ADVOCACY AND INFLUENCE, JDRF DRIVES FUNDING FROM OTHER SOURCES INTO T1D RESEARCH AND HAS HELPED SECURE PASSAGE OF THE SPECIAL DIABETES PROGRAM, PUTTING NEARLY $3.5 BILLION IN FEDERAL FUNDING TOWARD T1D RESEARCH OVER THE LAST TWO DECADES. ADDITIONALLY, JDRF FOUNDED THE JDRF T1D FUND (T1DFUND.ORG), WHICH IS A WHOLLY OWNED ENTITY OF JDRF. THE T1D FUND IS A VENTURE PHILANTHROPY FUND ACCELERATING LIFE-CHANGING SOLUTIONS TO TREAT, PREVENT, AND CURE T1D THROUGH CATALYTIC COMMERCIAL INVESTMENTS. THROUGH ITS INVESTMENTS IN PARTNERSHIP WITH PRIVATE CAPITAL, INCLUDING VENTURE CAPITAL, PHARMA, AND FOUNDATIONS, THE T1D FUND SEEKS TO ATTRACT THE PRIVATE INVESTMENT NECESSARY TO ADVANCE DRUGS, DEVICES, DIAGNOSTICS, AND VACCINES TO HELP PEOPLE LIVING WITH T1D AND THOSE WHO ARE AT RISK OF DEVELOPING THE DISEASE. THE T1D FUND INVESTS IN OPPORTUNITIES THAT DRIVE OUR MISSION, WITH AN EXCLUSIVE FOCUS ON THE MOST PROMISING COMMERCIAL OPPORTUNITIES. ALL FUNDS GO DIRECTLY TO SUPPORT COMPANIES DEVELOPING APPROACHES TO TREAT, PREVENT, AND CURE T1D. IN ACCORDANCE WITH GAAP, THE T1D FUND'S TOTAL INVESTMENTS AS OF JUNE 30, 2023, TOTALING $70.1 MILLION, ARE REFLECTED IN THE BALANCE SHEET (PART X) AND NOT INCLUDED WITHIN JDRF'S RESEARCH-RELATED MISSION EXPENSE. JDRF'S DIVERSIFIED RESEARCH PORTFOLIO INCLUDES A FOCUS ON CURING T1D AND IMPROVING LIVES. CURING T1D WE FACE TWO KEY CHALLENGES IN CURING T1D. WE MUST PREVENT, STOP, OR REVERSE THE (1) LOSS OF INSULIN-PRODUCING BETA CELLS AND (2) THE IMMUNE SYSTEM'S ATTACK ON BETA CELLS. JDRF IS ACCELERATING OUR WORK IN CURING T1D BY FOCUSING ON THREE AREAS THAT HAVE ADVANCED DRAMATICALLY OVER THE YEARS: SCREENING FOR RISK OF T1D, CELL THERAPIES, AND DISEASE-MODIFYING THERAPIES. SCREENING FOR RISK OF T1D: FOCUS ON EXPANDING SCREENING FOR T1D-RELATED AUTOANTIBODIES AND SCREENING AWARENESS. DONOR-FUNDED RESEARCH HAS DISCOVERED THAT HAVING TWO OR MORE T1D-SPECIFIC ANTIBODIES MEANS THAT YOU HAVE AN ALMOST 100% CHANCE OF DEVELOPING DIABETES IN YOUR LIFETIME. WITH ONE BLOOD TEST, YOU CAN FIND OUT-BEFORE SYMPTOMS APPEAR-IF YOU ARE AT RISK. THIS CAN REDUCE THE RISK OF DIABETIC KETOACIDOSIS AND HOSPITALIZATION AT THE ONSET OF SYMPTOMS AND IDENTIFY PEOPLE WHO CAN TAKE PART IN CLINICAL TRIALS TO DELAY OR PREVENT T1D. CELL THERAPIES: FOCUS ON REPLACING INSULIN-PRODUCING BETA CELLS FROM OUTSIDE SOURCES SUCH AS STEM CELLS OR NON-HUMAN CELLS. THROUGH DONOR-FUNDED RESEARCH, WE NOW KNOW THAT WHEN SOMEONE HAS T1D, THEIR OWN BODY BEGINS ATTACKING AND DESTROYING THE BETA CELLS THAT CREATE INSULIN. IF WE CAN REPLACE BETA CELLS, WE CAN HELP FIND CURES FOR T1D. THERE IS EARLY BUT CRUCIAL PROGRESS SEEN IN RECENTLY REPORTED CLINICAL TRIALS WHERE BETA CELL REPLACEMENT HAS MADE ADVANCES TOWARD INSULIN INDEPENDENCE, BETTER T1D CONTROL, AND LONGEVITY OF THE THERAPIES. DISEASE-MODIFYING THERAPIES: RESEARCH HAS SHOWN THAT A PERSON'S IMMUNE SYSTEM MISTAKENLY DESTROYS THE BODY'S BETA CELLS, RENDERING THE PERSON INSULIN-DEPENDENT FOR LIFE. IF WE CAN FIND WAYS TO KEEP THE IMMUNE SYSTEM FROM ATTACKING AND DESTROYING BETA CELLS, PROVIDE WAYS TO PROTECT AND TO SPUR THEM, AND DEVELOP TREATMENTS THAT CAN SLOW, HALT, OR REVERSE T1D, AT ANY AGE OR STAGE OF THE DISEASE, WE WILL BE ON THE PATHWAY TO PREVENTION AND CURES FOR T1D. IMPROVING LIVES T1D BRINGS WITH IT DAILY STRUGGLES AND STRESSES THAT THAT MAKE THE CHALLENGES OF LIVING A HEALTHY AND LONG LIFE WITH T1D VERY REAL. JDRF FIGHTS EVERY DAY TO ADVANCE RESEARCH THAT CAN REDUCE THE BURDEN OF LIVING WITH T1D AND KEEP PEOPLE AS HEALTHY AS POSSIBLE UNTIL WE FIND CURES. SPECIFICALLY, WE ARE STRIVING TO IMPROVE LIVES BY ACCELERATING THE DEVELOPMENT OF DRUGS, DEVICES, BEHAVIORAL HEALTH INTERVENTIONS, AND COMBINATIONS OF THESE, TO IMPROVE SHORT- AND LONG-TERM HEALTH OUTCOMES AND QUALITY OF LIFE, THROUGH THE FOLLOWING THREE PROGRAMS. GLUCOSE CONTROL: WE KNOW THAT FEWER THAN 30% OF PEOPLE WITH T1D IN THE U.S. CONSISTENTLY MAINTAIN TARGET BLOOD-GLUCOSE LEVELS-MEANING THAT 70% ARE AT RISK OF SERIOUS HEALTH ISSUES. AIMING TO ENSURE OUR COMMUNITY IS HEALTHY WHEN CURES ARE FOUND, WE WILL CONTINUE TO FOCUS ON HELPING THOSE WITH T1D MANAGE GLUCOSE LEVELS AND OVERALL METABOLIC BALANCE, INCLUDING IMPROVED ARTIFICIAL PANCREAS TECHNOLOGY, DEVELOPING NEXT-GENERATION INSULINS, AND DEVELOPING NEW DRUGS THAT CONTROL GLUCOSE AND OTHER METABOLIC FACTORS IN NOVEL WAYS. COMPLICATIONS: FOCUS ON ACCELERATING THERAPIES THAT PREVENT AND TREAT EYE, KIDNEY, AND HEART DISEASE. MORE THAN 90% OF PEOPLE WITH T1D DEVELOP SOME LEVEL OF EYE DISEASE WITHIN 20 YEARS OF DIAGNOSIS, 1 IN 4 DEVELOP KIDNEY DISEASE, AND HEART ATTACKS AND STROKES CAUSE APPROXIMATELY 3 OUT OF EVERY 4 DEATHS IN PEOPLE WITH T1D. JDRF DIRECTS FUNDS TO DEVELOP AND IMPROVE EYE, KIDNEY, AND HEART DISEASE TREATMENTS, SO THAT PEOPLE AT RISK CAN TAKE STEPS TO INTERVENE EARLY IN THE DISEASE PROCESS. PSYCHOSOCIAL HEALTH: FOCUS ON REDUCING THE PSYCHOSOCIAL CHALLENGES OF T1D. EARLY RESEARCH HAS SHOWN THAT THE BURDEN OF LIVING WITH T1D TAKES A TOLL BEYOND THE PHYSICAL COMPLICATIONS, OFTEN AFFECTING PEOPLE'S SOCIAL, BEHAVIORAL, AND EMOTIONAL WELL-BEING, KNOWN COLLECTIVELY AS PSYCHOSOCIAL HEALTH. WE AIM TO REDUCE THE CHALLENGES THROUGH INCREASING THE NUMBER OF AND PROVIDING ACCESS TO PSYCHOLOGISTS TRAINED IN T1D, SUPPORTING RESEARCH INITIATIVES TO IMPROVE PSYCHOSOCIAL HEALTH AND OUTCOMES, AND EDUCATING THE T1D COMMUNITY ABOUT THE PSYCHOSOCIAL IMPACT OF THE DISEASE. FORM 990, PART III, LINE 4B: PUBLIC EDUCATION JDRF IS UNIQUELY QUALIFIED TO PROVIDE PUBLIC EDUCATION ABOUT TYPE 1 DIABETES AND ITS COMPLICATIONS. JDRF'S EFFORTS IMPACT NOT ONLY THE MILLIONS OF PEOPLE LIVING WITH T1D, THEIR FAMILIES, AND THE GENERAL PUBLIC, BUT ALSO THOSE AT RISK FOR DEVELOPING THE DISEASE. T1D STRIKES BOTH CHILDREN AND ADULTS, AND THE CRITICAL ADJUSTMENT PERIOD FOLLOWING A DIAGNOSIS CAN BE OVERWHELMING. THAT'S WHY WE SUPPORT FAMILIES NAVIGATING THIS CHALLENGING TIME. JDRF ALSO EDUCATES PEOPLE ABOUT THE WARNING SIGNS OF T1D, AIMED AT ENSURING TIMELY DIAGNOSES AND REDUCING THE POTENTIAL CATASTROPHIC CONSEQUENCES OF UNDIAGNOSED T1D. JDRF ALSO PROVIDES INFORMATION AND UPDATES ABOUT CURRENT RESEARCH DIRECTIONS AND PROGRESS AND ABOUT HUMAN CLINICAL TRIALS THAT ARE SEEKING PARTICIPANTS (INCLUDING THROUGH JDRF'S CLINICAL TRIALS CONNECTION MATCHING TOOL: JDRF.ORG/CLINICAL-TRIALS). THROUGH ALL OF OUR NATIONAL U.S. CHAPTERS; FIVE INTERNATIONAL AFFILIATES IN AUSTRALIA, CANADA, ISRAEL, THE NETHERLANDS, AND UNITED KINGDOM; THE 30,000 MEMBERS OF OUR SOCIAL NETWORK, TYPEONENATION; AND MORE THAN ONE MILLION SUPPORTERS, JDRF FIGHTS TO MEET THE T1D COMMUNITY'S DIVERSE NEEDS, CONNECTING PEOPLE WITH LOCAL SUPPORT, EXPERT RESOURCES, AND THE GLOBAL EFFORT TO CREATE A WORLD WITHOUT T1D. FORM 990, PART III, LINE 4C: RESEARCH SUPPORT JDRF'S IN-HOUSE TEAM OF SKILLED AND CREDENTIALED SCIENTIFIC, POLICY, AND GOVERNMENT RELATIONS PROFESSIONALS PLAYS A CRITICAL ROLE IN LEADING AND SUPPORTING THE RESEARCH STRATEGY AND DISTRIBUTION OF RESEARCH FUNDS FROM JDRF-AND OUR PARTNER ORGANIZATIONS-TOWARD CREATING A WORLD WITHOUT T1D. OUR PROFESSIONALS IDENTIFY, EVALUATE, AND INFLUENCE GROUNDBREAKING RESEARCH FOR FUNDING AND WORK WITH OTHER FOUNDATIONS, GOVERNMENTS, AND INDUSTRY PARTNERS TO ACCELERATE THE MISSION WE ALL SHARE. JDRF PROFESSIONALS WORK WITH REGULATORY AND POLICY OFFICIALS TO ENSURE RESEARCH CAN PROCEED WITHOUT DELAY AND THAT ADVANCES ARE WELL UNDERSTOOD BY HEALTHCARE DECISION MAKERS. AS PART OF THESE EFFORTS, JDRF ORGANIZES AND FUNDS SCIENTIFIC MEETINGS, SYMPOSIA, AND CONFERENCES TO ENSURE THAT JDRF'S RESEARCH STRATEGY IS ALIGNED WITH THE NEEDS OF THE T1D COMMUNITY AND ALLOW JDRF TO PROVIDE SCIENTIFIC UPDATES ON THE RESEARCH IT MANAGES. THIS EFFORT ENSURES THAT ALL THE RESEARCH IS CONTINUALLY SHARED AND BUILT UPON BY T1D RESEARCHERS AROUND THE GLOBE. THE STRATEGIC ADVISORY PANEL (SAP) IS COMPOSED OF FIVE ESTABLISHED T1D EXPERTS IN VARIOUS ASPECTS OF THE FIELD, INCLUDING PEDIATRIC ENDOCRINOLOGY, PREVENTION, AND TREATMENT OF T1D, IMMUNOTHERAPIES, REGULATORY, AND DRUG DEVELOPMENT. THE SAP CONTRIBUTES TO JDRF SCIENTISTS' STRATEGIC PLANNING AROUND RESEARCH FUNDING GOALS AND PRIORITIES. JDRF'S WORK TO BRING TOGETHER THE BEST MINDS IN THE FIELD ENHANCES JDRF'S ABILITY TO FORECAST FUTURE SCIENTIFIC DIRECTION, JUDGE THE POTENTIAL EFFECTIVENESS OF NEW PATHWAYS, AND IDENTIFY GAPS WHERE JDRF FUNDING CAN MAKE THE MOST IMPACT. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS JDRF HAS A RIGOROUS STANDARD APPROACH TO REVIEWING ITS 990. THE ORGANIZATION'S ACCOUNTING MANAGER WORKS WITH ITS OUTSIDE TAX PREPARERS TO PREPARE THE RETURN AND ALL SUPPORTING SCHEDULES. THE DRAFT RETURN IS REVIEWED BY A NUMBER OF INDIVIDUALS, INCLUDING JDRF'S CHIEF FINANCIAL OFFICER, OTHER EXECUTIVES, ITS EXTERNAL SENIOR TAX ADVISOR AND OTHERS AS NECESSARY TO ENSURE ACCURACY. ANY QUESTIONS AND CHANGES WITH RESPECT TO THE DRAFT RETURNS ARE ADDRESSED. FOLLOWING THIS PROCESS, THE RETURN IS REVIEWED BY JDRF'S AUDIT AND RISK COMMITTEE OF THE BOARD OF DIRECTORS WITH ITS OUTSIDE TAX ADVISORS. ONCE APPROVED, THE RETURN IS DISTRIBUTED TO ALL MEMBERS OF JDRF'S BOARD OF DIRECTORS FOR REVIEW AND COMMENT BEFORE IT IS FILED WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY COVERED PERSONS COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM AND ACKNOWLEDGE THE JDRF CODE OF ETHICS AT THE BEGINNING OF EACH FISCAL YEAR. COVERED PERSONS INCLUDE: MEMBERS OF THE INTERNATIONAL BOARD OF DIRECTORS, DIRECTORS EMERITUS, MEMBERS OF THE GLOBAL MISSION BOARD, CHAPTER DIRECTORS AND OFFICERS, DIRECTORS OF THE JDRF T1D FUND, AND MEMBERS OF THE T1D FUND INVESTMENT COMMITTEE. WHEN A CONFLICT IS DISCLOSED, THE COVERED PERSON SHALL ABSTAIN FROM PARTICIPATING IN DECISIONS AND/OR DISCUSSIONS INVOLVING JDRF'S BUSINESS OR RELATIONSHIP WITH THE RELEVANT THIRD PARTY. IF THE COVERED PERSON IS ASKED TO ABSTAIN, THE COVERED PERSON MAY STILL BE PERMITTED TO STATE HIS OR HER POSITION ON SUCH MATTER AND TO ANSWER PERTINENT QUESTIONS AND INQUIRIES RELATING THERETO. THE COVERED PERSON MAY BE ASKED TO LEAVE THE MEETING DURING THE DISCUSSION OF AND/OR VOTE ON THE MATTER INVOLVING THE RELEVANT THIRD PARTY. FORM 990, PART VI, SECTION B, LINE 15 EXECUTIVE COMPENSATION POLICY JDRF'S BOARD OF DIRECTORS CHARGES A TALENT AND COMPENSATION COMMITTEE TO DEVELOP AND RECOMMEND A COMPENSATION PHILOSOPHY THAT APPLIES TO ALL EMPLOYEES OF THE FOUNDATION, INCLUDING RECOMMENDATIONS REGARDING THE COMPENSATION AND BENEFITS OF FOUNDATION SENIOR MANAGEMENT FOR APPROVAL BY THE BOARD OF DIRECTORS. THE COMMITTEE WORKS IN COLLABORATION WITH THE CEO AND THE CHIEF HUMAN RESOURCES OFFICER AND OTHER SENIOR STAFF PERSONNEL IN THE JDRF HUMAN RESOURCES DEPARTMENT TO ENSURE THAT 1) THE FOUNDATION'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) JDRF IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE FOUNDATION'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. TO ATTRACT AND RETAIN TOP SCIENTIFIC AND EXECUTIVE TALENT TO ADVANCE ITS MISSION, THE FOUNDATION PAYS COMPETITIVE AND APPROPRIATE SALARIES AS DETERMINED BY ANALYSIS OF RELIABLE DATA AND INPUT FROM INDEPENDENT THIRD-PARTY CONSULTANTS. THE REVIEW OF FOUNDATION EXECUTIVE COMPENSATION AND BENEFITS UNDER THE PROCEDURES NOTED ABOVE IS COMPLETED ANNUALLY BY AN INDEPENDENT COMPENSATION COMMITTEE, AND THE BASIS FOR THEIR DETERMINATION IS DOCUMENTED CONTEMPORANEOUSLY IN THE MINUTES OF THE COMMITTEE'S MEETINGS, INCLUDING MOST RECENTLY ON JUNE 30, 2023. SIMILARLY, A SEPARATE TALENT AND COMPENSATION COMMITTEE OF THE T1D FUND IS CHARGED WITH ENSURING THAT 1) THE FUND'S TALENT STRATEGY SUPPORTS AND IS ALIGNED WITH ITS OVERALL ORGANIZATION STRATEGIES; 2) JDRF IS IN COMPLIANCE WITH IRS GUIDELINES FOR DETERMINING REASONABLENESS IN PAY PRACTICES; AND 3) OVERALL COMPENSATION FOR THE FUND'S KEY EXECUTIVES IS COMPETITIVE AND ALIGNED WITH PAY PHILOSOPHY. FORM 990, PART VI, SECTION C, LINE 19 PUBLIC DOCUMENTS THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE: WWW.JDRF.ORG. THE PUBLIC MAY ACCESS COPIES OF JDRF'S W-9, ANNUAL REPORTS, 990 TAX RETURNS, 501(C)(3) IRS LETTER, AND AUDITED FINANCIALS, AT THE FOLLOWING LINK: WWW.JDRF.ORG/ABOUT/FINANCIALS. JDRF T1D FUND LLC C/O JDRF - 200 VESEY ST 28TH FL NEW YORK NY 10281 274967989 FUNDR/INVEST DE 19470110 184443000 JDRF INTERNATIONAL SCHEDULE R, PART I, LINE (1B) THE PRIMARY ACTIVITY FOR THE JDRF T1D FUND IS FUNDRAISING AND INVESTING IN TYPE 1 DIABETES RESEARCH. PLEASE SEE DETAILED DESCRIPTION ON SCHEDULE O, PART III, LINE 4A, STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS FOR RESEARCH GRANTS.